Malaria chemotherapy trial at a minimal effective dose of mefloquine/sulfadoxine/pyrimethamine compared with equivalent doses of sulfadoxine/pyrimethamine or mefloquine alone

American Journal of Tropical Medicine and Hygiene

Volumn 58, Issue 5, 1998, Pages 619-624

  Lell, Bertrand ^a,b   Lehman, Leopold G ^a,b   Schmidt Ott, J Ruprecht ^a,b   Sturchler, Dieter ^c   Handschin, Jurg ^d   Kremsner, Peter G ^a,b,e  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Hôpital Albert Schweitzer   (Gabon)

^c FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; FANSIDAR; FANSIMEF; MEFLOQUINE;

ABDOMINAL PAIN; ADOLESCENT; ANTIMICROBIAL THERAPY; ARTICLE; CASE FINDING; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SYNTHESIS; FEMALE; GABON; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; PARASITEMIA; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME;

MURINAE; PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0031862883     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1998.58.619     Document Type: Article

References (26)

1. Burchard GD, Horstmann RD, Wernsdorfer WH, Dietrich M, 1984. Plasmodium falciparum-malaria: resistance to chloroquine, but sensitivity to mefloquine in the Gabon. A prospective in-vitro study. Trop Med Parasitol 35: 1-4.
2. Winkler S, Brandts C, Wernsdorter WH, Graninger W, Bienzle U, Kremsner PG, 1994. Drug sensitivity of Plasmodium falciparum in Gabon. Activity correlations between various antimalarials. Trop Med Parasitol 45: 214-218.
3. Kremsner PG, Winkler S, Brandts C, Neifer S, Bienzle U, Graninger W, 1994. Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis 169: 467-470.
4. Starchier D, 1989. How much malaria is there worldwide? Parasitol Today 5: 39-40.
5. Metzger W, Mordmuller B, Graninger W, Bienzle U, Kremsner PG, 1995. Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. J Antimicrob Chemother 36: 723-728.
6. Sowunmi A, Oduola AMI, Salako LA, 1995. Artemether treatment of sulfadoxine/pyrimethamine-resistant Plasmodium falciparum malaria in children. Trans R Soc Trop Med Hyg 89: 435-436.
7. Wolday D, Kibreab T, Bukenya D, Hodes R, 1995. Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Trans R Soc Trop Med Hyg 89: 654-656.
8. Brockelman CR, Thanomsub B, Bhisutthibhand J, 1989. Mefloquine sulfadoxine pyrimethamine (MSP) combination delays in vitro emergence of mefloquine resistance in multiple drug resistant Plasmodium falciparum. Southeast Asian J Trop Med Public Health 20: 371-378.
9. Merkli B, Richle R, Peters W, 1980. The inhibitory effect of a drug combination on the development of mefloquine resistance in Plasmodium berghei. Ann Trop Med Parasitol 74: 1-9.
10. Peters W, Robinson BL, 1984. The chemotherapy of rodent malaria XXXV. Further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and 'P. berghei NS'. Ann Trop Med Parasitol 78: 459-466.
11. Radloff PD, Phillips J, Nkeyi M, Sturchler D, Mittelholzer W, Kremsner PG, 1996. Arteflene compared with mefloquine for treating Plasmodium falciparum malaria in children. Am J Trop Med Hyg 55: 259-262.
12. Radloff PD, Philipps J, Nkeyi M, Handschin J, Sturchler D, Kremsner PG, 1995. Minimal effective dose of mefloquine/ sulfadoxine/pyrimethamine in mild Plasmodium falciparum malaria. J Antimicrob Chemother 36: 586-587.
13. Hellgren U, Kihamia CM, Bergqvist Y, Lebbad M, Premji Z, Rombo L, 1990. Standard and reduced doses of sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum in Tanzania, with determination of drug concentrations and susceptibility in vitro. Trans R Soc Trop Med Hyg 84: 469-473.
14. Sarikabhuti B, Keschamrus N, Noeypatimanond S, Weidekamm E, Leimer R, Wemsdorfer W, Kolle EU, 1988. Plasma concentrations of sulfadoxine in healthy and malaria infected Thai subjects. Acta Trop 45: 217-224.
15. Hellgren U, Kihamia CM, Bergqvist Y, Rombo L, 1991. Standard and reduced doses of mefloquine for treatment of Plasmodium falciparum in Tanzania: whole blood concentrations in relation to adverse reactions, in vivo response, and in vitro susceptibility. Am J Trop Med Hyg 45: 254-262.
16. Weidekamm E, Schwartz DE, Dubach UC, Weber B, 1987. Single-dose investigation of possible interactions between the components of the antimalarial combination Fansimef®. Chemotherapy 33: 259-265.
17. Karbwang J, Back DJ, Bunnag D, Breckenridge AM, 1990. Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria. Bull World Health Organ 68: 633-638.
18. Fontanet AL, Johnston BD, Walker AM, Bergqvist Y, Hellgren U, Rooney W, 1994. Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine. Hull World Health Organ 72: 73-78.
19. Karbwang J, Bangchang KN, Thimasarn K, Rooney W, Bunnag D, Harinasuta T, 1993. Mefloquine level monitoring in patients with multidrug resistant Plasmodium falciparum on the Thai Myanmar border. Southeast Asian J Trop Med Public Health 24: 505-507.
20. Boudreau EF, Fleckenstein L, Pang LW, Childs GE, Schrocdcr AC, Ratnaratom B, Phintuyothin P, 1990. Mefloquine kinetics in cured and recrudescent patients with acute falciparum malaria and in healthy volunteers. Clin Pharmacol Ther 48: 399-409.
21. Slutsker LM, Khoromana CO, Payne D, Allen CR, Wirima JJ, Heymann DL, Patchen L, Steketee RW, 1990. Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. Bull World Health Organ 68: 53-59.
22. Basco LK, Gillotin C, Gimenez F, Farinotti R, Le Bras J, 1991. Absence of antimalarial activity or interaction with mefloquine enantiomers in vitro of the main human metabolite of mefloquine. Trans K Soc Trop Med Hyg 85: 208-209.
23. Wildling E, Winkler S, Kremsner PG, Brandts C, Jenne L, Wemsdorfer WH, 1995. Malaria epidemiology in the province of Moyen Ogooue, Gabon. Trop Med Parasitol 46: 77-82.
24. Peters W, 1995. Mefloquine/sulfadoxine/pyrimethamine for malaria. Trans R Soc Trop Med Hyg 89: 699.
25. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster HK, Edstein M, Phaipun L, Thew KL, White NJ, 1991. Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 337: 1140-1143.
26. Sowunmi A, Oduola AMJ, 1995. Open comparison of meflo-quine, mefloquine/sulfadoxine/pyrimethamine and chloroquine in acute uncomplicated falciparum malaria in children. Trans R Soc Trop Med Hyg 89: 303-305.